Ascendis Pharma (ASND) Tops Q2 EPS by 132c

Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of EUR2.83, EUR1.32 better than the analyst estimate of EUR1.51. Revenue for the quarter came in at EUR339.28 million versus the consensus estimate of EUR326.45 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Lake Street Starts RF Industries Ltd. (RFIL) at Buy
• Cingulate posts wider Q2 loss as SG&A spending more than doubles